Patients deserve the best
CIRCULOGENE begins with a patented methodology which increased the yield of DNA and effectively preserves fragile RNA. Our use of next-generation sequencing (NGS) and polymerase chain reaction (PCR) instrumentation provides both the breadth of DNA menu and the depth for RNA detection. These two technological advancements are the basis for our best-in-class menu offerings, including TumorClear, ImmunoClear, MSI Complete, and Hereditary Panels.
CIRCULOGENE can complement tissue biopsy as recommended by the International Association for the Study of Lung Cancer (IASLC) for enabling a faster time to treatment, providing the right first-line treatment, and resulting in better patient outcomes.
Each patient’s cancer is unique, understanding the origins and severity of the cancers aids oncologists to personalize the patient’s treatment plan at the time of diagnosis and throughout their cancer journey.
The CIRCULOGENE Best-in-Class Advantage
CIRCULOGENE begins some tests with a proprietary enrichment process resulting to increase the yield of cfDNA and preserve fragile cfRNA yields. By eliminating the need for a purification step, CIRCULOGENE overcomes the limitations associated with sample volume requirements. This process preserves and extracts fragile cfRNA, enabling fusions and plasma PD-L1 to be effectively detected.
CIRCULOGENE Announces Appointment of Bob Gasparini to Board of Directors
BIRMINGHAM, Ala. and Pensacola, Fla. (December 8, 2022) – CIRCULOGENE is an innovative liquid biopsy company transforming precision…
CIRCULOGENE shares results of remarkable rectal cancer study
FOR IMMEDIATE RELEASE CIRCULOGENE shares results of remarkable rectal cancer study Identifying mismatch repair-deficient (MMRd)…